Evolus, Inc. ( (EOLS) ) has released its Q2 earnings. Here is a breakdown of the information Evolus, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Evolus, Inc. is a global performance beauty company focused on redefining the aesthetic injectable market with its innovative consumer brands and digital platform. In its latest earnings report for the second quarter of 2025, Evolus announced a 4% increase in global net revenue to $69.4 million, driven by the successful launch of Evolysse™ and robust international market performance. Despite a challenging U.S. market for aesthetic procedures, the company maintained a strong market share with its flagship product Jeuveau®.
The company’s financial performance was marked by Evolysse™ generating $9.7 million in revenue, marking a record launch for a filler product in over a decade. Evolus also reported a significant increase in its customer base and loyalty program membership, indicating growing consumer adoption. However, the company faced a GAAP loss from operations of $10.2 million, attributed to investments in new product launches and cost structure optimization.
Evolus has adjusted its 2025 net revenue guidance to a range of $295 million to $305 million and aims to achieve meaningful profitability by the fourth quarter of 2025. The company is also focusing on strategic cost savings and plans to launch new products in the coming years to sustain growth. Evolus remains committed to achieving a total net revenue goal of $700 million by 2028.
Looking ahead, Evolus is optimistic about its growth prospects, with expectations of an improved U.S. toxin market and continued international expansion. The company plans to leverage its existing infrastructure to achieve a non-GAAP operating income margin of 20% by 2028, reflecting a positive outlook for its long-term financial performance.